Clinical Effectiveness of Lurasidone Monotherapy in Patients with Acute Episodes of Schizophrenia and Associated Symptoms of Depression

Abstract

AIM: We endeavored to evaluate the efficacy of Lurasidone at doses of 40–160 mg per day on symptoms of schizophrenia associated with symptoms of depression in real clinical practice in a Russian patient population.

METHODS: One hundred sixty eight patients aged 18–65 years old, who at the time of the start of the observation were being treated in a hospital or day hospital due to an exacerbation of paranoid schizophrenia accompanied by symptoms of depression, were prescribed lurasidone. Treatment with lurasidone and other concomitant drugs, their prescription, withdrawal, selection, and dose modifications were determined based on the indications for the use of those drugs and the recommended doses in the instructions, clinical need, and patient interests, rather than by the goals of the study. During the observation period, the severity of depressive symptoms according to the Calgary Depression Scale (CDSS) and that of psychotic symptoms according to the Positive and Negative Syndrome Scale (PANSS) were assessed six times (before the start of treatment and then on the 4^th, 7^th, 14^th, 28^th, and 42^nd days).

RESULTS: A statistically significant reduction in the severity of the symptoms was observed with the use of lurasidone in doses ranging from 40 mg to 160 mg per day. The fastest and most significant (p <0.001) reductions in the total PANSS and CDSS scores were observed with lurasidone 120 mg. A somewhat lower efficacy of lurasidone was observed at a dose of 160 mg. The largest reductions in the total PANSS and CDSS scores with lurasidone 120 mg were associated with the highest survival rate and the longest median time from treatment initiation to discontinuation or follow-up. The most commonly reported side effects with lurasidone in this study (nausea, akathisia, tremor and drowsiness) were consistent with the known safety profile of the drug. Adverse events in most cases were assessed as mild, or occasionally moderate.

CONCLUSION: A six-week prospective observational study of the real-world clinical effectiveness of lurasidone in doses ranging from 40 mg to 160 mg per day established statistically and clinically significant improvements in both psychotic and depressive symptoms in patients with acute exacerbation of schizophrenia and associated symptoms of depression.

Keywords

lurasidone / schizophrenia / depression / exacerbation of schizophrenia / second-generation antipsychotic / psychopharmacotherapy

References

[1] Lindenmayer JP, Grochowski S, Kay SR. Schizophrenic patients with depression: psychopathological profiles and relationship with negative symptoms. Compr Psychiatry. 1991 Nov-Dec;32(6):528–533. doi: 10.1016/0010-440x(91)90032-8

[2] Siris SG. Depression in schizophrenia: perspective in the era of “Atypical” antipsychotic agents. Am J Psychiatry. 2000 Sep;157(9):1379–1389. doi: 10.1176/appi.ajp.157.9.1379

[3] Majadas S, Olivares J, Galan J, Diez T. Prevalence of depression and its relationship with other clinical characteristics in a sample of patients with stable schizophrenia. Compr Psychiatry. 2012 Feb;53(2):145–151. doi: 10.1016/j.comppsych.2011.03.009

[4] Miura I, Nosaka T, Yabe H, Hagi K. Antidepressive Effect of Antipsychotics in the Treatment of Schizophrenia: Meta-Regression Analysis of Randomized Placebo-Controlled Trials. Int J Neuropsychopharmacol. 2021 Mar 17;24(3):200–215. doi: 10.1093/ijnp/pyaa082

[5] Liu R, Fang X, Yu L, Wang D, Wu Z, Guo C, Teng X, Ren J, Zhang C. Gender Differences of Schizophrenia Patients With and Without Depressive Symptoms in Clinical Characteristics. Front Psychiatry. 2021;12:792019. doi: 10.3389/fpsyt.2021.792019

[6] Upthegrove R, Marwaha S, Birchwood M. Depression and Schizophrenia: Cause, Consequence, or Trans-diagnostic Issue? Schizophr Bull. 2017 Mar 1;43(2):240–244. doi: 10.1093/schbul/sbw097

[7] Tandon R, Gaebel W, Barch DM, Bustillo J, Gur RE, Heckers S, Malaspina D, Owen MJ, Schultz S, Tsuang M, et al. Definition and description of schizophrenia in the DSM-5. Schizophr Res. 2013 Oct;150(1):3–10. doi: 10.1016/j.schres.2013.05.028

[8] Reininghaus U, Bohnke JR, Hosang G, Farmer A, Burns T, McGuffin P, Bentall RP. Evaluation of the validity and utility of a transdiagnostic psychosis dimension encompassing schizophrenia and bipolar disorder. Br J Psychiatry. 2016 Aug;209(2):107–113. doi: 10.1192/bjp.bp.115.167882

[9] Reininghaus U, Bohnke JR, Chavez-Baldini U, Gibbons R, Ivleva E, Clementz BA, Pearlson GD, Keshavan MS, Sweeney JA, Tamminga CA. Transdiagnostic dimensions of psychosis in the Bipolar-Schizophrenia Network on Intermediate Phenotypes (B-SNIP). World Psychiatry. 2019 Feb;18(1):67–76. doi: 10.1002/wps.20607

[10] Tamminga CA, Ivleva EI, Keshavan MS, Pearlson GD, Clementz BA, Witte B, Morris DW, Bishop J, Thaker GK, Sweeney JA. Clinical phenotypes of psychosis in the Bipolar-Schizophrenia Network on Intermediate Phenotypes (B-SNIP). Am J Psychiatry. 2013 Nov; 170(11):1263–1274. doi: 10.1176/appi.ajp.2013.12101339

[11] Krynicki CR, Upthegrove R, Deakin JFW, Barnes TRE. The relationship between negative symptoms and depression in schizophrenia: a systematic review. Acta Psychiatr Scand. 2018 May;137(5):380–390. doi: 10.1111/acps.12873

[12] An der Heiden W, Leber A, Hafner H. Negative symptoms and their association with depressive symptoms in the long-term course of schizophrenia. Eur Arch Psychiatry Clin Neurosci. 2016 Aug;266(5):387–396. doi: 10.1007/s00406-016-0697-2

[13] Felmet K, Zisook S, Kasckow JW. Elderly patients with schizophrenia and depression: diagnosis and treatment. Clin Schizophr Relat Psychoses. 2011 Jan;4(4):239–250. doi: 10.3371/CSRP.4.4.4

[14] Jhawer H, Sidhu M, Patel RS. Missed Diagnosis of Major Depressive Disorder with Catatonia Features. Brain Sci. 2019 Feb 2;9(2):31. doi: 10.3390/brainsci9020031

[15] Borisova PO. Nosological Dilemma and Clinical Polymorphism of the Catatonia Phenomenon. Psychiatry. 2020;18(2):61–70. doi: 10.30629/2618-6667-2020-18-2-61-70

[16] Mazo GE, Gorbachyov SE. [Depression in schizophrenia: experiences and approaches to diagnosis and treatment in psychiatric practice]. Socialnaja i klinicheskaja psihiatrija. 2009;19(4):5–14. Russian.

[17] Helfer B, Samara MT, Huhn M, Klupp E, Leucht C, Zhu Y, Engel RR, Leucht S. Efficacy and Safety of Antidepressants Added to Antipsychotics for Schizophrenia: A Systematic Review and Meta-Analysis. Am J Psychiatry. 2016 Sep 1;173(9):876–886. doi: 10.1176/appi.ajp.2016.15081035

[18] Gregory A, Mallikarjun P, Upthegrove R. Treatment of depression in schizophrenia: systematic review and meta-analysis. Br J Psychiatry. 2017 Oct;211(4):198–204. doi: 10.1192/bjp.bp.116.190520

[19] Dorofeikova MV, Petrova NN. [Personalised approach to therapy of depression of schizophrenia]. Modern therapy of mental disorders. 2021;(3):32–44. Russian. doi: 10.21265/PSYPH.2021.99.14.004

[20] psychiatr.ru site of the Russian Society of Psychiatrists [Internet]. Federal clinical guidelines for the diagnosis and treatment of schizophrenia [cited 22 June 2022]. Available from: http://psychiatr.ru/download/1269.

[21] Whitehead C, Moss S, Cardno A, Lewis G. Antidepressants for the treatment of depression in people with schizophrenia: a systematic review. Psychol Med. 2003 May;33(4):589–599. doi: 10.1017/s0033291703007645

[22] Bosanac P, Castle DJ. Schizophrenia and depression. Med J Aust. 2013 Sep 16;199(S6):S36–39. doi: 10.5694/mja12.10516

[23] Tapp A, Kilzieh N, Wood AE, Raskind M, Tandon R. Depression in patients with schizophrenia during an acute psychotic episode. Compr Psychiatry. 2001 Jul-Aug;42(4):314–318. doi: 10.1053/comp.2001.24577

[24] Ishibashi T, Horisawa T, Tokuda K, Ishiyama T, Ogasa M, Tagashira R, Matsumoto K, Nishikawa H, Ueda Y, Toma S, et al. Pharmacological profile of lurasidone, a novel antipsychotic agent with potent 5-hydroxytryptamine 7 (5-HT7) and 5-HT1A receptor activity. J Pharmacol Exp Ther. 2010 Jul;334(1):171–181. doi: 10.1124/jpet.110.167346

[25] Citrome L. Schizophrenia relapse, patient considerations, and potential role of lurasidone. Patient Prefer Adherence. 2016;10:1529–1537. doi: 10.2147/PPA.S45401

[26] Murai T, Nakako T, Ikeda K, Ikejiri M, Ishiyama T, Taiji M. Lack of dopamine D4 receptor affinity contributes to the procognitive effect of lurasidone. Behav Brain Res. 2014 Mar 15;261:26–30. doi: 10.1016/j.bbr.2013.11.036

[27] Caccia S, Pasina L, Nobili A. Critical appraisal of lurasidone in the management of schizophrenia. Neuropsychiatr Dis Treat. 2012;8:155–168. doi: 10.2147/NDT.S18059

[28] Mauri MC, Paletta S, Maffini M, Colasanti A, Dragogna F, Di Pace C, Altamura AC. Clinical pharmacology of atypical antipsychotics: an update. EXCLI J. 2014;13:1163–1191.

[29] Huhn M, Nikolakopoulou A, Schneider-Thoma J, Krause M, Samara M, Peter N, Arndt T, Backers L, Rothe P, Cipriani A, et al. Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis. Lancet. 2019 Sep 14;394(10202):939–951. doi: 10.1016/S0140-6736(19)31135-3

[30] Meyer JM, Mao Y, Pikalov A, Cucchiaro J, Loebel A. Weight change during long-term treatment with lurasidone: pooled analysis of studies in patients with schizophrenia. Int Clin Psychopharmacol. 2015 Nov;30(6):342–350. doi: 10.1097/YIC.0000000000000091

[31] Meyer JM, Ng-Mak DS, Chuang CC, Rajagopalan K, Loebel A. Weight changes before and after lurasidone treatment: a real-world analysis using electronic health records. Ann Gen Psychiatry. 2017;16:36. doi: 10.1186/s12991-017-0159-x

[32] Riva MA, Albert U, de Filippis S, Vita A, De Berardis D. Identification of clinical phenotypes in schizophrenia: the role of lurasidone. Ther Adv Psychopharmacol. 2021;11:20451253211012250. doi: 10.1177/20451253211012250

[33] Nakamura M, Ogasa M, Guarino J, Phillips D, Severs J, Cucchiaro J, Loebel A. Lurasidone in the treatment of acute schizophrenia: a double-blind, placebo-controlled trial. J Clin Psychiatry. 2009 Jun;70(6):829–836. doi: 10.4088/JCP.08m04905

[34] Meltzer HY, Cucchiaro J, Silva R, Ogasa M, Phillips D, Xu J, Kalali AH, Schweizer E, Pikalov A, Loebel A. Lurasidone in the treatment of schizophrenia: a randomized, double-blind, placebo- and olanzapine-controlled study. Am J Psychiatry. 2011 Sep;168(9):957–967. doi: 10.1176/appi.ajp.2011.10060907

[35] Nasrallah HA, Cucchiaro JB, Mao Y, Pikalov AA, Loebel AD. Lurasidone for the treatment of depressive symptoms in schizophrenia: analysis of 4 pooled, 6-week, placebo-controlled studies. CNS Spectr. 2015 Apr;20(2):140–147. doi: 10.1017/S1092852914000285

[36] Loebel A, Cucchiaro J, Xu J, Sarma K, Pikalov A, Kane JM. Effectiveness of lurasidone vs. quetiapine XR for relapse prevention in schizophrenia: a 12-month, double-blind, noninferiority study. Schizophr Res. 2013 Jun;147(1):95–102. doi: 10.1016/j.schres.2013.03.013

[37] Marder SR, Davis JM, Chouinard G. The effects of risperidone on the five dimensions of schizophrenia derived by factor analysis: combined results of the North American trials. J Clin Psychiatry. 1997 Dec;58(12):538–546. doi: 10.4088/jcp.v58n1205

[38] Hopkins SC, Ogirala A, Loebel A, Koblan KS. Transformed PANSS Factors Intended to Reduce Pseudospecificity Among Symptom Domains and Enhance Understanding of Symptom Change in Antipsychotic-Treated Patients With Schizophrenia. Schizophr Bull. 2018 Apr 6;44(3):593–602. doi: 10.1093/schbul/sbx101

[39] Harvey PD, Siu CO, Loebel AD. Insight and Treatment Outcomes in Schizophrenia: Post-hoc Analysis of a Long-term, Double-blind Study Comparing Lurasidone and Quetiapine XR. Innov Clin Neurosci. 2017 Dec 1;14(11–12):23–29.

[40] Oleichik IV, Baranov PA, Shishkovskaia TI, Sizov SV. Efficacy and Safety of the Third-Generation Atypical Antipsychotic Lurazidone in the Treatment of Depression in Schizophrenia. Current Therapy of Mental Disorders. 2021;(2):28–35. Russian. doi: 10.21265/PSYPH.2021.57.2.004

[41] Rajagopalan K, Wade S, Meyer N, Loebel A. Real-world adherence assessment of lurasidone and other oral atypical antipsychotics among patients with schizophrenia: an administrative claims analysis. Curr Med Res Opin. 2017 May;33(5):813–820. doi: 10.1080/03007995.2017.1284656

[42] Loebel A, Cucchiaro J, Silva R, Kroger H, Hsu J, Sarma K, Sachs G. Lurasidone monotherapy in the treatment of bipolar I depression: a randomized, double-blind, placebo-controlled study. Am J Psychiatry. 2014 Feb;171(2):160–168. doi: 10.1176/appi.ajp.2013.13070984

[43] Loebel A, Cucchiaro J, Silva R, Kroger H, Sarma K, Xu J, Calabrese JR. Lurasidone as adjunctive therapy with lithium or valproate for the treatment of bipolar I depression: a randomized, double-blind, placebo-controlled study. Am J Psychiatry. 2014 Feb;171(2):169–177. doi: 10.1176/appi.ajp.2013.13070985

[44] Maslennikov NV, Cukarzi EE, Mosolov SN. Algorithm for biological therapy of depression in schizophrenia. Current therapy of mental disorders. 2019;(2):31–40. Russian. doi: 10.21265/PSYPH.2019.34.92.005

[45] Amri I, Millier A, Toumi M. Minimum Clinically Important Difference in the Calgary Depression Scale for Schizophrenia. Value Health. 2014 Nov;17(7):A766. doi: 10.1016/j.jval.2014.08.288

[46] Addington J, Shah H, Liu L, Addington D. Reliability and validity of the Calgary Depression Scale for Schizophrenia (CDSS) in youth at clinical high risk for psychosis. Schizophr Res. 2014 Mar;153(1–3):64–67. doi: 10.1016/j.schres.2013.12.014

[47] Ivanova E, Khan A, Liharska L, Reznik A, Kuzmin S, Kushnir O, Agarkov A, Bokhan N, Pogorelova T, Khomenko O, et al. Validation of the Russian Version of the Positive and Negative Syndrome Scale (PANSS-Ru) and Normative Data. Innov Clin Neurosci. 2018 Oct 1;15(9–10):32–48.

[48] Loebel A, Silva R, Goldman R, Watabe K, Cucchiaro J, Citrome L, Kane JM. Lurasidone Dose Escalation in Early Nonresponding Patients With Schizophrenia: A Randomized, Placebo-Controlled Study. J Clin Psychiatry. 2016 Dec;77(12):1672–1680. doi: 10.4088/JCP.16m10698

[49] Goldman R, Loebel A, Cucchiaro J, Deng L, Findling RL. Efficacy and Safety of Lurasidone in Adolescents with Schizophrenia: A 6-Week, Randomized Placebo-Controlled Study. J Child Adolesc Psychopharmacol. 2017 Aug;27(6):516–525. doi: 10.1089/cap.2016.0189

Funding

OAO Angelini Pharma RusОАО "Анджелини Фарма Рус"

RIGHTS & PERMISSIONS

Reznik A.M., Syunyakov T.S., Akhmerova I.Y., Butylin D.Y., Vasilenko A.O., Gvozdetckii A.N., Gizatullin T.R., Gilmanshina G.V., Golosov E.A., Kolchev S. ., Linova L.P., Miron D.V., Mudrak A.V., Oleichik I.V., Sizov S.V., Tarakanova E.A., Chesnokova O.I.